индекс пгп чомпонент маилто ?тмпл=чомпонент&темплате=беез5&линк=173бе9чффд4ч5д111а81ч2бфч8216д3б4б3е7е43
Skin lesions in coronavirus infection caused by the SARS-CoV-2 virus are divided into seven categories. The first category includes skin angiitis caused directly by COVID-19 infection, against which the walls of small vessels of the dermis are damaged by immune complexes circulating in the blood. Angiitis is localized on the skin of the upper and lower extremities. They look like frostbite, painful, itchy. Such manifestations usually occur in young patients with a mild course of the disease, appear in the late stages and last about 12 days.
The second category includes papular-vesicular rashes, which are characterized by acute clinical manifestations in the form of chickenpox, more similar to prickly heat, occurring against a background of high fever and increased sweating.
Mikhail Yurchuk is from the Khmelnytsky region. After school, the man worked at a glass factory and a furniture factory. However, at the age of 26, he decided to become a professional military man.
“Since childhood, I have dreamed of becoming a military man. For me, this is about honor, duty. First, I served in a missile brigade, I was a rocket scientist, then I went to a military college for non-commissioned officers and finally went to the airborne brigade,” says Mikhail Yurchuk.
When a full-scale war began, the military served in the Donbass. Then the brigade was moved to the Kharkov region. Michael was wounded there.
Treatment with corticosteroids (especially prednisolone ≥20 mg/day or equivalent) is associated with an increased risk of infection. However, it is unclear whether corticosteroid therapy is associated with an increased risk of developing COVID-19 or its complications. Data on budesonide, a topical corticosteroid with low systemic bioavailability, show that these drugs are associated with significantly fewer side effects compared to systemic corticosteroids and their side effects are close to placebo.
If possible, corticosteroids should be avoided and a rapid dose reduction considered, and a switch to budesonide is recommended. This must be taken into account, taking into account the risk of exacerbation of CKD.
If a patient with COPD is in contact with a person with COVID-19 or develops COVID-19, it is recommended to gradually reduce the dose of corticosteroids, the use of budesonide is preferred, but taking into account the severity of COPD and the risk of exacerbation.
